CN108125917A - 一种米格列奈钙制剂的制备的方法 - Google Patents
一种米格列奈钙制剂的制备的方法 Download PDFInfo
- Publication number
- CN108125917A CN108125917A CN201711408359.2A CN201711408359A CN108125917A CN 108125917 A CN108125917 A CN 108125917A CN 201711408359 A CN201711408359 A CN 201711408359A CN 108125917 A CN108125917 A CN 108125917A
- Authority
- CN
- China
- Prior art keywords
- starch
- mixing
- low
- whole grain
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003365 mitiglinide Drugs 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 53
- 239000008107 starch Substances 0.000 claims abstract description 53
- 235000019698 starch Nutrition 0.000 claims abstract description 53
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 38
- 238000002156 mixing Methods 0.000 claims abstract description 37
- 235000020985 whole grains Nutrition 0.000 claims abstract description 36
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 32
- 239000008101 lactose Substances 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 29
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 23
- 239000011734 sodium Substances 0.000 claims abstract description 23
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 23
- 229940032147 starch Drugs 0.000 claims abstract description 22
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 18
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001375 lactose Drugs 0.000 claims abstract description 7
- PMRVFZXOCRHXFE-FMEJWYFOSA-L Kad 1229 Chemical compound [Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 PMRVFZXOCRHXFE-FMEJWYFOSA-L 0.000 claims abstract 18
- 239000000243 solution Substances 0.000 claims description 13
- 239000011812 mixed powder Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 235000001465 calcium Nutrition 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract 1
- QEVLNUAVAONTEW-UZYHXJQGSA-L calcium;(2s)-4-[(3as,7ar)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;dihydrate Chemical compound O.O.[Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 QEVLNUAVAONTEW-UZYHXJQGSA-L 0.000 description 44
- 238000004090 dissolution Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108010065691 Biphasic Insulins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000189 biphasic insulin Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
试验号 | 粉碎设备 | 通过率% | 单个杂质% | 总杂质% | 溶出度% |
Ⅰ | 机械式粉碎机 | 80 | 0.08 | 0.21 | 60 |
Ⅱ | 气流粉碎机 | 83 | 0.09 | 0.19 | 71 |
Ⅲ | 研磨机 | 82 | 0.09 | 0.19 | 73 |
Ⅳ | 低温超微粉碎机 | 90 | 0.07 | 0.15 | 79 |
试验号 | 通过率% | 单个杂质% | 总杂质% | 溶出度% |
Ⅰ | 98 | 0.06 | 0.16 | 81 |
Ⅱ | 97 | 0.07 | 0.14 | 82 |
Ⅲ | 98 | 0.08 | 0.15 | 80 |
Ⅳ | 99 | 0.05 | 0.13 | 95 |
Ⅴ | 94 | 0.06 | 0.18 | 80 |
试验号 | 均匀度 | 片重差异% | 溶出度% |
Ⅰ | 10 | 7 | 90 |
Ⅱ | 12 | 6 | 93 |
Ⅲ | 8 | 4 | 95 |
Ⅳ | 14 | 6 | 92 |
试验号 | 均匀度 | 片重差异% | 溶出度% |
Ⅰ | 9 | 6.5 | 92 |
Ⅱ | 12 | 5.7 | 92 |
Ⅲ | 10 | 6.1 | 94 |
Ⅳ | 6 | 3.8 | 96 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711408359.2A CN108125917B (zh) | 2017-12-22 | 2017-12-22 | 一种米格列奈钙制剂的制备的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711408359.2A CN108125917B (zh) | 2017-12-22 | 2017-12-22 | 一种米格列奈钙制剂的制备的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108125917A true CN108125917A (zh) | 2018-06-08 |
CN108125917B CN108125917B (zh) | 2018-11-20 |
Family
ID=62391652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711408359.2A Active CN108125917B (zh) | 2017-12-22 | 2017-12-22 | 一种米格列奈钙制剂的制备的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108125917B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110568100A (zh) * | 2019-09-12 | 2019-12-13 | 江西济民可信金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742721A (zh) * | 2005-09-29 | 2006-03-08 | 周卓和 | 米格列奈钙制剂及其制备方法 |
CN104224736A (zh) * | 2013-06-21 | 2014-12-24 | 哈药集团三精制药股份有限公司 | 一种辛伐他汀片的制备方法 |
CN105560197A (zh) * | 2015-12-30 | 2016-05-11 | 宜昌东阳光长江药业股份有限公司 | 一种快速溶出的米格列奈钙制剂及其制备和检测方法 |
-
2017
- 2017-12-22 CN CN201711408359.2A patent/CN108125917B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742721A (zh) * | 2005-09-29 | 2006-03-08 | 周卓和 | 米格列奈钙制剂及其制备方法 |
CN104224736A (zh) * | 2013-06-21 | 2014-12-24 | 哈药集团三精制药股份有限公司 | 一种辛伐他汀片的制备方法 |
CN105560197A (zh) * | 2015-12-30 | 2016-05-11 | 宜昌东阳光长江药业股份有限公司 | 一种快速溶出的米格列奈钙制剂及其制备和检测方法 |
Non-Patent Citations (1)
Title |
---|
余明远: "食品超微粉碎技术研究新进展", 《福建农业科技》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110568100A (zh) * | 2019-09-12 | 2019-12-13 | 江西济民可信金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108125917B (zh) | 2018-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103494785B (zh) | 一种孟鲁司特钠咀嚼片及其制备方法 | |
CN106667952A (zh) | 一种帕布昔利布药物组合物及其制备方法 | |
CN103494774B (zh) | 一种癸氧喹酯干混悬剂的制备方法 | |
CN104306344B (zh) | 一种阿齐沙坦片剂及其制备工艺 | |
CN105640913A (zh) | 一种奥美沙坦酯片及其制备方法 | |
CN105147614B (zh) | 一种包含bibw 2992ma2的固体制剂及其制备方法 | |
CN105030705B (zh) | 一种抗癌药物盐酸厄洛替尼片剂及其制备方法 | |
CN104546686B (zh) | 一种枸橼酸莫沙必利共研磨物及其制备方法和含其药物组合物 | |
CN105412026B (zh) | 盐酸阿考替胺片及其制备方法 | |
CN101744852B (zh) | 刺五加泡腾片的制备方法及其产品 | |
CN108125917B (zh) | 一种米格列奈钙制剂的制备的方法 | |
CN108553433A (zh) | 一种阿齐沙坦片及其制备方法 | |
CN104523651B (zh) | 一种伏格列波糖胶囊及其制备方法 | |
CN105732517B (zh) | 包含烟酰胺为前驱体的5-氟尿嘧啶药物共晶的药物制剂及其制备方法 | |
CN101185713A (zh) | 一种用于治疗跌仆损伤的药物制剂及其制备方法和质量控制方法 | |
CN101829044B (zh) | 一种他米巴罗汀固体制剂及其制备方法 | |
CN103655512B (zh) | 一种硝酸芬替康唑***软胶囊及其制备方法 | |
CN110638768A (zh) | 一种治疗男性***功能障碍药物的制备方法 | |
CN105616368B (zh) | 一种孟鲁司特钠片剂及其制备方法 | |
CN111000812B (zh) | 一种拉考沙胺片的制备方法 | |
CN104352465B (zh) | 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法 | |
CN102920893A (zh) | 十五味萝蒂明目片及其制备工艺 | |
CN103709329B (zh) | 一种妇炎康分散片药用辅料化合物及其制备方法与应用 | |
CN102861131B (zh) | 一种六味丁香片及其制备工艺、检测方法 | |
CN105596341A (zh) | 一种琥珀酸曲格列汀固体制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 336000 Yuanzhou pharmaceutical industry park, Jiangxi, Yichun Co-patentee after: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Patentee after: JIANGXI JIMINKEXIN PHARMACEUTICAL Co.,Ltd. Address before: 336000 Yuanzhou pharmaceutical industry park, Jiangxi, Yichun Co-patentee before: JIANGXI JIMINKEXIN JINSHUIBAO PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGXI JIMINKEXIN PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of miglinide calcium preparation Effective date of registration: 20211224 Granted publication date: 20181120 Pledgee: Bank of China Limited Nanchang Qingyunpu sub branch Pledgor: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Registration number: Y2021980016165 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220902 Granted publication date: 20181120 Pledgee: Bank of China Limited Nanchang Qingyunpu sub branch Pledgor: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Registration number: Y2021980016165 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of preparation method of mitiglinide calcium preparation Effective date of registration: 20220905 Granted publication date: 20181120 Pledgee: Bank of China Limited Nanchang Qingyunpu sub branch Pledgor: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Registration number: Y2022980014590 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230830 Granted publication date: 20181120 Pledgee: Bank of China Limited Nanchang Qingyunpu sub branch Pledgor: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Registration number: Y2022980014590 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Method for the Preparation of Miglinide Calcium Preparation Effective date of registration: 20230831 Granted publication date: 20181120 Pledgee: Bank of China Limited Nanchang Qingyunpu sub branch Pledgor: Jiangxi Jinshuibao Pharmaceutical Co.,Ltd. Registration number: Y2023980054963 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |